×


Injectable Drug Delivery Devices Market - In-Depth Analysis

Injectable Drug Delivery Devices Market, by device type (Conventional, Self-injectable, Prefilled Syringes, connected smart devices), parenteral route (Intradermal, Subcutaneous, Intramuscular, Intravenous), End-User (Hospitals, Homecare Settings, Clinics, Others), Region Global Market Analysis and Forecast 2022-2028

  • Report ID : IMR-16150 |
  • Category : Healthcare  |
  • Published Date : March 2022 |
  • Format :   IMR Report Formats   IMR Report Formats   IMR Report Formats

Global Injectable Drug Delivery Devices Market Overview

The technology utilized to deliver the drug to the target body site for drug release and absorption, or the subsequent transport of the active components across biological membranes to the site of action, is referred to as drug delivery. The method in which a drug is administered can have a substantial impact on its efficacy. The development of various drug delivery systems (DDSs) has enabled greater control of drug pharmacokinetics, pharmacodynamics, toxicity, immunogenicity, and efficacy. The best-suited delivery method for a specific drug molecule can optimize the performance of a specific drug inside the body. Injectable devices deliver drugs directly into the bloodstream. This is the best way to administer a drug quickly and precisely since the drug enters systemic circulation without the delay associated with absorption processes, exerting its therapeutic effect faster than any other route. Injectable drug administration is a traditional approach that is still widely used today. The rising number of people suffering from diabetes and chronic diseases has accelerated the growth of the injectable drug delivery device market.

Key Factors and Market Dynamics in Injectable Drug Delivery Devices:

Drivers

Next-Generation Drug Delivery Formulations - BeloGal Technology
New medication formulations that are not particularly water-soluble are becoming more common. It is estimated that 40% of medications with market approval and almost 90% of compounds in drug discovery pipelines are poorly soluble in aqueous solutions and/or have very low permeability to allow for sufficient and reproducible absorption from the gastrointestinal tract (GIT) following oral administration. BeloGal, a novel technology, offers a highly promising solution to nearly all formulation challenges of this type. It wraps the insoluble API in a biomimetic chemical polymer-based cover and directs the API to the liver or lung while avoiding other organs such as the heart. The majority of these medications are administered intravenously. Following the successful clinical development of the first BeloGal-based drug, the technology is expected to become the gold standard for intravenous drug delivery to the liver and lung, allowing for an entirely new level of innovation and clinical benefit for both drug delivery and organ-targeting, self-navigating drug formulations, thereby supporting the growth of the injectable drug delivery devices market throughout the forecast period.

Restraints

Contamination from previously used injectables and needlestick injuries can result in serious problems that require further remediation, and these complications frequently lead to additional challenges in disease management. In some circumstances, alternate medication delivery routes, such as oral administration, are favored over injections because they eliminate toxicity issues. Furthermore, strict regulations may restrict the usage of IDD forms. Several concerns have been raised in recent years about the sterility of injectables, which has resulted in a decrease in the number of approved production facilities that manufacture these products, and thus a shortage of these drugs in the market. Legal regulations by other countries on the usage of syringes for drug administration may hamper the growth of the injectable drug delivery devices market over the forecast period.

Opportunities

Microneedles-The Future of Drug Delivery
Microneedles, which are thinner than human hair, are frequently made from a hydrogel-forming polymer similar to that used to make soft contact lenses. Microneedles rapidly absorb fluid from the puncture site and swell, generating a jelly-like material while remaining rigid in a dry condition so that they can pierce the skin. Medicines can be administered into the body or biomarkers can be picked up for monitoring purposes via this relatively painless needle injection. Depending on their intended use, the needles can also be made as solid, coated, or hollow. After perforation, solid microneedles can carry pharmaceuticals into the skin, whereas coated microneedles have a film of medicine pasted over them that is then released into the body. Drugs can be injected directly into the skin through holes in the needles using hollow microneedles. This MedTech sector presents a lucrative opportunity for market participants, as demand for painless injectable devices is expected to rise throughout the forecasted timeframe.

Covid-19 Impact On Injectable Drug Delivery Devices Market

The COVID-19 pandemic has had devastating effects on several industry verticals globally. To constrain the number of cases and slow the coronavirus spread, various public health guidelines were implemented in different countries across the globe. COVID-19 protocols ranging from declaring national emergency states, enforcing stay-at-home orders, closing nonessential business operations and schools, banning public gatherings, imposing curfews, distributing digital passes, and allowing police to restrict citizen movements within a country, as well as closing international borders. The ability of Robo advisers to minimise irrational behaviour and bad & impulsive decision-making during a pandemic contributes significantly to the worldwide market's growth. With the growing vaccination rate, governments are uplifting the protocols to give a boost to the stagnant economy. Like other industries, Injectable Drug Delivery Devices Market have experienced slowdown the growth, however market is expected bounce back as restrictions are being lifted up by governments across the globe.

Market Segmentation

By Type, Injectable Drug Delivery Devices has been segmented into:

  • Devices
  • Formulations

By Packaging Formulations, Injectable Drug Delivery Devices has been segmented into:

  • Ampoules
  • Vials
  • Cartridges
  • Bottles

By Therapeutic Application, Injectable Drug Delivery Devices has been segmented into:

  • Autoimmune Diseases
  • Hormonal Disorders
  • Orphan Diseases
  • Cancer
  • Others

By Usage Patter, Injectable Drug Delivery Devices has been segmented into:

  • Curative Care
  • Immunization
  • Others

By Site of Administration, Injectable Drug Delivery Devices has been segmented into:

  • Skin
  • Circulatory/Musculoskeletal System
  • Organs
  • Central Nervous System

By Distribution Channel, Injectable Drug Delivery Devices has been segmented into:

  • Hospital
  • Retail Pharmacy Stores

Regions and Countries Level Analysis:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
  • Asia-Pacific (China, India, Japan, Southeast Asia etc.)
  • South America (Brazil, Argentina etc.)
  • Middle East & Africa (Saudi Arabia, South Africa etc.)

By type, the connected smart devices segment is anticipated to develop at the highest CAGR over the forecast period. Pharma 4.0 is accelerating the convergence of injection systems and information systems, including the development of a new generation of connected autoinjectors that combine personalized dosing with data capture and reporting capabilities. This delivery system not only simplifies dosing but also provides doctors and patients with a new level of digital visibility and insight into each course of therapy, helping the segment's growth. Due to the growing number of diabetic patients, the self-injectable category is expected to dominate the market. In recent years, the number of individuals that require injectable insulin has increased. Similarly, the number of patients suffering from spondylitis and cancer is also rising thus, strengthening the growth of the segment.

By parenteral route, the sub-cutaneous segment is expected to lead the growth of the injectable drug delivery devices market in the projected timeframe. A subcutaneous injection is given beneath the skin into the fat layer just below the dermis. Since the tissue areas have fewer blood arteries, absorption via the subcutaneous route is slow and sustained. It has a slower action than intravenous but a faster action than intradermal. Measles vaccine, insulin, goserelin, and morphine are some of the major drugs administered utilizing sub-cutaneous injections. The continuous rise in diabetic patients has stimulated the demand for sub-cutaneous injectable drug delivery devices. According to IDF, the total number of diabetic individuals was 537 million in 2021, which is expected to reach 643 million by 2030.

By end-users, the home care settings segment is anticipated to develop at the highest CAGR attributed to the rise in user-friendly injectable home medications. For instance, in May 2021, Eli Lilly and Company signed strategic international agreements with four companies: DexCom, Inc., Glooko Inc., myDiabby Healthcare, and Roche, to integrate data and technology to help streamline diabetes management. These firms provide distinct diabetes management solutions that will work with Lilly's Tempo Pen™ and Tempo Smart Button™. This will make the administration of insulin pens easier in homecare situations. Similar launches by other companies are expected to support the growth of the segment.

Players Covered in Injectable Drug Delivery Devices market are :

  • Becton
  • Dickinson and Company (U.S.)
  • Pfizer Inc. (U.S.)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Eli Lilly and Company (U.S.)
  • Baxter International Inc. (U.S.)
  • Schott AG (Germany)
  • Gerresheimer (Germany)
  • Ypsomed (Switzerland)
  • B. Braun Melsungen (Germany)

Regional Analysis of Injectable Drug Delivery Devices Market:

The Asia-Pacific region is anticipated to lead the growth of the injectable drug delivery devices market during the projected timeframe attributed to the high density of the geriatric population. China and India are the most populated countries in the world. High population density and the prevalence of chronic disorders are the main factors that can upsurge the spread of viral infections. The COVID-19 pandemic that originated in China rapidly spread to the other parts of the Asian countries and the rest of the globe. As the number of patients were increasing, the demand for syringes also soared. Furthermore, the vaccination initiatives that were started utilized syringes for administration. Concomitantly, the number of patients having the chronic disorder, cancer, and other medical condition that requires injectable drugs is also rising thus, supporting the expansion of the market in this region.

The North American region is estimated to have the second highest share of the injectable drug delivery devices market owing to the growing diabetic population. According to IDF, in North America and the Caribbean, the number of diabetic individuals was 51 million in 2021, and it is projected to reach 63 million by 2045. The 24% rise in the diabetic population is estimated to boost the sales of injectable insulin. Moreover, the prevalence of seasonal influenza is further bolstering the growth of the market. According to CDC, for the 2020-2021 season, manufacturers have projected they will provide as many as 194 to 198 million doses of influenza vaccine for the U.S. market thus, stimulating the development of the injectable drug delivery devices market in this region.

The market in the European region is anticipated to grow at a significant growth rate attributed to the increasing prevalence of chronic diseases. More than half of European individuals suffer from neurological disorders. According to the European Academy of Neurology, approximately 308 million individuals had one or the other kind of neurological disorder in 2017. Furthermore, diabetes is also common in this region. According to IDF, 61 million population was estimated to be diabetic in 2021, projected to reach 69 million by 2045. Thus, the growing number of chronic disorders will strengthen the growth of the injectable drug delivery devices market.

Recent Industry Developments in Injectable Drug Delivery Devices Market:

  • In October 2021, in collaboration with Aptar Pharma, Becton, Dickinson, and Company (BD) developed the BD SCF PremiumCoat Plunger Stopperade to facilitate the injection of biologics into subcutaneous tissue using a -mL pre-filled syringe.
  • In October 2021, the world's first autoinjector for prefilled syringes with integrated connection was presented by Ypsomed. The YpsoMate autoinjector for prefilled syringes is a dependable and safe device for subcutaneous self-medication. These allow people with chronic conditions to treat themselves at home, reducing the strain on the medical system.

Frequently Asked Questions :

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Base Year
 1.6 Scope of The Study
 1.7 Market Segmentation

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Report Description
 3.2 Market Overview: Market Definition and Scope
 3.3 Porter's Five Forces Analysis
  3.3.1 Bargaining Power of Supplier
  3.3.2 Threat of New Entrants
  3.3.3 Threat of Substitutes
  3.3.4 Competitive Rivalry
  3.3.5 Bargaining Power Among Buyers
 3.4 Industry Value Chain Analysis
 3.5 Market Dynamics
  3.5.1 Drivers
  3.5.2 Restraints
  3.5.3 Opportunities
  3.5.4 Challenges
 3.6 Pestle Analysis
 3.7 Analysis of the Impact of Covid-19

Chapter 4: Injectable Drug Delivery Devices Market by Type
 4.1 Injectable Drug Delivery Devices Market Overview By Type (2016-2027)
 4.2 Devices
  4.2.1 Market Overview
  4.2.2 Key Market Trends, Growth Factors and Opportunities
  4.2.3 Historic and Forecasted Market Size (2016-2027)
  4.2.4 Historic and Forecasted Market Size By Region (2016-2027)
 4.3 Formulations
  4.3.1 Market Overview
  4.3.2 Key Market Trends, Growth Factors and Opportunities
  4.3.3 Historic and Forecasted Market Size (2016-2027)
  4.3.4 Historic and Forecasted Market Size By Region (2016-2027)

Chapter 5: Injectable Drug Delivery Devices Market by Packaging Formulations
 5.1 Injectable Drug Delivery Devices Market Overview By Packaging Formulations (2016-2027)
 5.2 Ampoules
  5.2.1 Market Overview
  5.2.2 Key Market Trends, Growth Factors and Opportunities
  5.2.3 Historic and Forecasted Market Size (2016-2027)
  5.2.4 Historic and Forecasted Market Size By Region (2016-2027)
 5.3 Vials
  5.3.1 Market Overview
  5.3.2 Key Market Trends, Growth Factors and Opportunities
  5.3.3 Historic and Forecasted Market Size (2016-2027)
  5.3.4 Historic and Forecasted Market Size By Region (2016-2027)
 5.4 Cartridges
  5.4.1 Market Overview
  5.4.2 Key Market Trends, Growth Factors and Opportunities
  5.4.3 Historic and Forecasted Market Size (2016-2027)
  5.4.4 Historic and Forecasted Market Size By Region (2016-2027)
 5.5 Bottles
  5.5.1 Market Overview
  5.5.2 Key Market Trends, Growth Factors and Opportunities
  5.5.3 Historic and Forecasted Market Size (2016-2027)
  5.5.4 Historic and Forecasted Market Size By Region (2016-2027)

Chapter 6: Injectable Drug Delivery Devices Market by Therapeutic Application
 6.1 Injectable Drug Delivery Devices Market Overview By Therapeutic Application (2016-2027)
 6.2 Autoimmune Diseases
  6.2.1 Market Overview
  6.2.2 Key Market Trends, Growth Factors and Opportunities
  6.2.3 Historic and Forecasted Market Size (2016-2027)
  6.2.4 Historic and Forecasted Market Size By Region (2016-2027)
 6.3 Hormonal Disorders
  6.3.1 Market Overview
  6.3.2 Key Market Trends, Growth Factors and Opportunities
  6.3.3 Historic and Forecasted Market Size (2016-2027)
  6.3.4 Historic and Forecasted Market Size By Region (2016-2027)
 6.4 Orphan Diseases
  6.4.1 Market Overview
  6.4.2 Key Market Trends, Growth Factors and Opportunities
  6.4.3 Historic and Forecasted Market Size (2016-2027)
  6.4.4 Historic and Forecasted Market Size By Region (2016-2027)
 6.5 Cancer
  6.5.1 Market Overview
  6.5.2 Key Market Trends, Growth Factors and Opportunities
  6.5.3 Historic and Forecasted Market Size (2016-2027)
  6.5.4 Historic and Forecasted Market Size By Region (2016-2027)
 6.6 Others
  6.6.1 Market Overview
  6.6.2 Key Market Trends, Growth Factors and Opportunities
  6.6.3 Historic and Forecasted Market Size (2016-2027)
  6.6.4 Historic and Forecasted Market Size By Region (2016-2027)

Chapter 7: Injectable Drug Delivery Devices Market by Usage Patter
 7.1 Injectable Drug Delivery Devices Market Overview By Usage Patter (2016-2027)
 7.2 Curative Care
  7.2.1 Market Overview
  7.2.2 Key Market Trends, Growth Factors and Opportunities
  7.2.3 Historic and Forecasted Market Size (2016-2027)
  7.2.4 Historic and Forecasted Market Size By Region (2016-2027)
 7.3 Immunization
  7.3.1 Market Overview
  7.3.2 Key Market Trends, Growth Factors and Opportunities
  7.3.3 Historic and Forecasted Market Size (2016-2027)
  7.3.4 Historic and Forecasted Market Size By Region (2016-2027)
 7.4 Others
  7.4.1 Market Overview
  7.4.2 Key Market Trends, Growth Factors and Opportunities
  7.4.3 Historic and Forecasted Market Size (2016-2027)
  7.4.4 Historic and Forecasted Market Size By Region (2016-2027)

Chapter 8: Injectable Drug Delivery Devices Market by Site of Administration
 8.1 Injectable Drug Delivery Devices Market Overview By Site of Administration (2016-2027)
 8.2 Skin
  8.2.1 Market Overview
  8.2.2 Key Market Trends, Growth Factors and Opportunities
  8.2.3 Historic and Forecasted Market Size (2016-2027)
  8.2.4 Historic and Forecasted Market Size By Region (2016-2027)
 8.3 Circulatory/Musculoskeletal System
  8.3.1 Market Overview
  8.3.2 Key Market Trends, Growth Factors and Opportunities
  8.3.3 Historic and Forecasted Market Size (2016-2027)
  8.3.4 Historic and Forecasted Market Size By Region (2016-2027)
 8.4 Organs
  8.4.1 Market Overview
  8.4.2 Key Market Trends, Growth Factors and Opportunities
  8.4.3 Historic and Forecasted Market Size (2016-2027)
  8.4.4 Historic and Forecasted Market Size By Region (2016-2027)
 8.5 Central Nervous System
  8.5.1 Market Overview
  8.5.2 Key Market Trends, Growth Factors and Opportunities
  8.5.3 Historic and Forecasted Market Size (2016-2027)
  8.5.4 Historic and Forecasted Market Size By Region (2016-2027)

Chapter 9: Injectable Drug Delivery Devices Market by Distribution Channel
 9.1 Injectable Drug Delivery Devices Market Overview By Distribution Channel (2016-2027)
 9.2 Hospital
  9.2.1 Market Overview
  9.2.2 Key Market Trends, Growth Factors and Opportunities
  9.2.3 Historic and Forecasted Market Size (2016-2027)
  9.2.4 Historic and Forecasted Market Size By Region (2016-2027)
 9.3 Retail Pharmacy Stores
  9.3.1 Market Overview
  9.3.2 Key Market Trends, Growth Factors and Opportunities
  9.3.3 Historic and Forecasted Market Size (2016-2027)
  9.3.4 Historic and Forecasted Market Size By Region (2016-2027)

Chapter 10: Company Profiles and Competitive Analysis
 10.1 Competitive Landscape
  10.1.1 Competition Analysis
  10.1.2 Strategies By Top Leading Players
  10.1.3 Mergers and Acquisitions
  10.1.4 Top Winning Strategies
 10.2 BECTON
  10.2.1 Company Overview
  10.2.2 Company Snapshot
  10.2.3 Business Performance
  10.2.4 Product Portfolio
  10.2.5 Key Strategic Moves and Recent Developments
 10.3 DICKINSON AND COMPANY (U.S.)
  10.3.1 Company Overview
  10.3.2 Company Snapshot
  10.3.3 Business Performance
  10.3.4 Product Portfolio
  10.3.5 Key Strategic Moves and Recent Developments
 10.4 PFIZER INC. (U.S.)
  10.4.1 Company Overview
  10.4.2 Company Snapshot
  10.4.3 Business Performance
  10.4.4 Product Portfolio
  10.4.5 Key Strategic Moves and Recent Developments
 10.5 TEVA PHARMACEUTICALS INDUSTRIES LTD. (ISRAEL)
  10.5.1 Company Overview
  10.5.2 Company Snapshot
  10.5.3 Business Performance
  10.5.4 Product Portfolio
  10.5.5 Key Strategic Moves and Recent Developments
 10.6 ELI LILLY AND COMPANY (U.S.)
  10.6.1 Company Overview
  10.6.2 Company Snapshot
  10.6.3 Business Performance
  10.6.4 Product Portfolio
  10.6.5 Key Strategic Moves and Recent Developments
 10.7 BAXTER INTERNATIONAL INC. (U.S.)
  10.7.1 Company Overview
  10.7.2 Company Snapshot
  10.7.3 Business Performance
  10.7.4 Product Portfolio
  10.7.5 Key Strategic Moves and Recent Developments
 10.8 SCHOTT AG (GERMANY)
  10.8.1 Company Overview
  10.8.2 Company Snapshot
  10.8.3 Business Performance
  10.8.4 Product Portfolio
  10.8.5 Key Strategic Moves and Recent Developments
 10.9 GERRESHEIMER (GERMANY)
  10.9.1 Company Overview
  10.9.2 Company Snapshot
  10.9.3 Business Performance
  10.9.4 Product Portfolio
  10.9.5 Key Strategic Moves and Recent Developments
 10.10 YPSOMED (SWITZERLAND)
  10.10.1 Company Overview
  10.10.2 Company Snapshot
  10.10.3 Business Performance
  10.10.4 Product Portfolio
  10.10.5 Key Strategic Moves and Recent Developments
 10.11 B. BRAUN MELSUNGEN (GERMANY)
  10.11.1 Company Overview
  10.11.2 Company Snapshot
  10.11.3 Business Performance
  10.11.4 Product Portfolio
  10.11.5 Key Strategic Moves and Recent Developments

Chapter 11: Global Injectable Drug Delivery Devices Market By Region
 11.1 Overview
 11.2 North America
  11.2.1 Market Overview
  11.2.2 Key Market Trends, Growth Factors and Opportunities
  11.2.2 Historic and Forecast Market Size by Type
  11.2.3 Historic and Forecast Market Size by Packaging Formulations
  11.2.4 Historic and Forecast Market Size by Therapeutic Application
  11.2.5 Historic and Forecast Market Size by Usage Patter
  11.2.6 Historic and Forecast Market Size by Site of Administration
  11.2.7 Historic and Forecast Market Size by Distribution Channel
  11.2.8 Historic and Forecast Market Size by Country
 11.3 Europe
  11.3.1 Market Overview
  11.3.2 Key Market Trends, Growth Factors and Opportunities
  11.3.2 Historic and Forecast Market Size by Type
  11.3.3 Historic and Forecast Market Size by Packaging Formulations
  11.3.4 Historic and Forecast Market Size by Therapeutic Application
  11.3.5 Historic and Forecast Market Size by Usage Patter
  11.3.6 Historic and Forecast Market Size by Site of Administration
  11.3.7 Historic and Forecast Market Size by Distribution Channel
  11.3.8 Historic and Forecast Market Size by Country
 11.4 Asia Pacific
  11.4.1 Market Overview
  11.4.2 Key Market Trends, Growth Factors and Opportunities
  11.4.2 Historic and Forecast Market Size by Type
  11.4.3 Historic and Forecast Market Size by Packaging Formulations
  11.4.4 Historic and Forecast Market Size by Therapeutic Application
  11.4.5 Historic and Forecast Market Size by Usage Patter
  11.4.6 Historic and Forecast Market Size by Site of Administration
  11.4.7 Historic and Forecast Market Size by Distribution Channel
  11.4.8 Historic and Forecast Market Size by Country
 11.5 Middle East & Africa
  11.5.1 Market Overview
  11.5.2 Key Market Trends, Growth Factors and Opportunities
  11.5.2 Historic and Forecast Market Size by Type
  11.5.3 Historic and Forecast Market Size by Packaging Formulations
  11.5.4 Historic and Forecast Market Size by Therapeutic Application
  11.5.5 Historic and Forecast Market Size by Usage Patter
  11.5.6 Historic and Forecast Market Size by Site of Administration
  11.5.7 Historic and Forecast Market Size by Distribution Channel
  11.5.8 Historic and Forecast Market Size by Country
 11.6 South America
  11.6.1 Market Overview
  11.6.2 Key Market Trends, Growth Factors and Opportunities
  11.6.2 Historic and Forecast Market Size by Type
  11.6.3 Historic and Forecast Market Size by Packaging Formulations
  11.6.4 Historic and Forecast Market Size by Therapeutic Application
  11.6.5 Historic and Forecast Market Size by Usage Patter
  11.6.6 Historic and Forecast Market Size by Site of Administration
  11.6.7 Historic and Forecast Market Size by Distribution Channel
  11.6.8 Historic and Forecast Market Size by Country

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. INJECTABLE DRUG DELIVERY DEVICES MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. INJECTABLE DRUG DELIVERY DEVICES MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. INJECTABLE DRUG DELIVERY DEVICES MARKET COMPETITIVE RIVALRY
TABLE 005. INJECTABLE DRUG DELIVERY DEVICES MARKET THREAT OF NEW ENTRANTS
TABLE 006. INJECTABLE DRUG DELIVERY DEVICES MARKET THREAT OF SUBSTITUTES
TABLE 007. INJECTABLE DRUG DELIVERY DEVICES MARKET BY TYPE
TABLE 008. DEVICES MARKET OVERVIEW (2016-2027)
TABLE 009. FORMULATIONS MARKET OVERVIEW (2016-2027)
TABLE 010. INJECTABLE DRUG DELIVERY DEVICES MARKET BY PACKAGING FORMULATIONS
TABLE 011. AMPOULES MARKET OVERVIEW (2016-2027)
TABLE 012. VIALS MARKET OVERVIEW (2016-2027)
TABLE 013. CARTRIDGES MARKET OVERVIEW (2016-2027)
TABLE 014. BOTTLES MARKET OVERVIEW (2016-2027)
TABLE 015. INJECTABLE DRUG DELIVERY DEVICES MARKET BY THERAPEUTIC APPLICATION
TABLE 016. AUTOIMMUNE DISEASES MARKET OVERVIEW (2016-2027)
TABLE 017. HORMONAL DISORDERS MARKET OVERVIEW (2016-2027)
TABLE 018. ORPHAN DISEASES MARKET OVERVIEW (2016-2027)
TABLE 019. CANCER MARKET OVERVIEW (2016-2027)
TABLE 020. OTHERS MARKET OVERVIEW (2016-2027)
TABLE 021. INJECTABLE DRUG DELIVERY DEVICES MARKET BY USAGE PATTER
TABLE 022. CURATIVE CARE MARKET OVERVIEW (2016-2027)
TABLE 023. IMMUNIZATION MARKET OVERVIEW (2016-2027)
TABLE 024. OTHERS MARKET OVERVIEW (2016-2027)
TABLE 025. INJECTABLE DRUG DELIVERY DEVICES MARKET BY SITE OF ADMINISTRATION
TABLE 026. SKIN MARKET OVERVIEW (2016-2027)
TABLE 027. CIRCULATORY/MUSCULOSKELETAL SYSTEM MARKET OVERVIEW (2016-2027)
TABLE 028. ORGANS MARKET OVERVIEW (2016-2027)
TABLE 029. CENTRAL NERVOUS SYSTEM MARKET OVERVIEW (2016-2027)
TABLE 030. INJECTABLE DRUG DELIVERY DEVICES MARKET BY DISTRIBUTION CHANNEL
TABLE 031. HOSPITAL MARKET OVERVIEW (2016-2027)
TABLE 032. RETAIL PHARMACY STORES MARKET OVERVIEW (2016-2027)
TABLE 033. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE (2016-2027)
TABLE 034. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PACKAGING FORMULATIONS (2016-2027)
TABLE 035. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY THERAPEUTIC APPLICATION (2016-2027)
TABLE 036. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USAGE PATTER (2016-2027)
TABLE 037. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY SITE OF ADMINISTRATION (2016-2027)
TABLE 038. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL (2016-2027)
TABLE 039. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY (2016-2027)
TABLE 040. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE (2016-2027)
TABLE 041. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PACKAGING FORMULATIONS (2016-2027)
TABLE 042. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET, BY THERAPEUTIC APPLICATION (2016-2027)
TABLE 043. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USAGE PATTER (2016-2027)
TABLE 044. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET, BY SITE OF ADMINISTRATION (2016-2027)
TABLE 045. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL (2016-2027)
TABLE 046. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY (2016-2027)
TABLE 047. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE (2016-2027)
TABLE 048. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PACKAGING FORMULATIONS (2016-2027)
TABLE 049. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET, BY THERAPEUTIC APPLICATION (2016-2027)
TABLE 050. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USAGE PATTER (2016-2027)
TABLE 051. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET, BY SITE OF ADMINISTRATION (2016-2027)
TABLE 052. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL (2016-2027)
TABLE 053. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY (2016-2027)
TABLE 054. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE (2016-2027)
TABLE 055. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PACKAGING FORMULATIONS (2016-2027)
TABLE 056. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY THERAPEUTIC APPLICATION (2016-2027)
TABLE 057. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USAGE PATTER (2016-2027)
TABLE 058. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY SITE OF ADMINISTRATION (2016-2027)
TABLE 059. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL (2016-2027)
TABLE 060. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY (2016-2027)
TABLE 061. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE (2016-2027)
TABLE 062. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PACKAGING FORMULATIONS (2016-2027)
TABLE 063. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY THERAPEUTIC APPLICATION (2016-2027)
TABLE 064. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USAGE PATTER (2016-2027)
TABLE 065. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY SITE OF ADMINISTRATION (2016-2027)
TABLE 066. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL (2016-2027)
TABLE 067. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY (2016-2027)
TABLE 068. BECTON: SNAPSHOT
TABLE 069. BECTON: BUSINESS PERFORMANCE
TABLE 070. BECTON: PRODUCT PORTFOLIO
TABLE 071. BECTON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. DICKINSON AND COMPANY (U.S.): SNAPSHOT
TABLE 072. DICKINSON AND COMPANY (U.S.): BUSINESS PERFORMANCE
TABLE 073. DICKINSON AND COMPANY (U.S.): PRODUCT PORTFOLIO
TABLE 074. DICKINSON AND COMPANY (U.S.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. PFIZER INC. (U.S.): SNAPSHOT
TABLE 075. PFIZER INC. (U.S.): BUSINESS PERFORMANCE
TABLE 076. PFIZER INC. (U.S.): PRODUCT PORTFOLIO
TABLE 077. PFIZER INC. (U.S.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. TEVA PHARMACEUTICALS INDUSTRIES LTD. (ISRAEL): SNAPSHOT
TABLE 078. TEVA PHARMACEUTICALS INDUSTRIES LTD. (ISRAEL): BUSINESS PERFORMANCE
TABLE 079. TEVA PHARMACEUTICALS INDUSTRIES LTD. (ISRAEL): PRODUCT PORTFOLIO
TABLE 080. TEVA PHARMACEUTICALS INDUSTRIES LTD. (ISRAEL): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. ELI LILLY AND COMPANY (U.S.): SNAPSHOT
TABLE 081. ELI LILLY AND COMPANY (U.S.): BUSINESS PERFORMANCE
TABLE 082. ELI LILLY AND COMPANY (U.S.): PRODUCT PORTFOLIO
TABLE 083. ELI LILLY AND COMPANY (U.S.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 083. BAXTER INTERNATIONAL INC. (U.S.): SNAPSHOT
TABLE 084. BAXTER INTERNATIONAL INC. (U.S.): BUSINESS PERFORMANCE
TABLE 085. BAXTER INTERNATIONAL INC. (U.S.): PRODUCT PORTFOLIO
TABLE 086. BAXTER INTERNATIONAL INC. (U.S.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 086. SCHOTT AG (GERMANY): SNAPSHOT
TABLE 087. SCHOTT AG (GERMANY): BUSINESS PERFORMANCE
TABLE 088. SCHOTT AG (GERMANY): PRODUCT PORTFOLIO
TABLE 089. SCHOTT AG (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 089. GERRESHEIMER (GERMANY): SNAPSHOT
TABLE 090. GERRESHEIMER (GERMANY): BUSINESS PERFORMANCE
TABLE 091. GERRESHEIMER (GERMANY): PRODUCT PORTFOLIO
TABLE 092. GERRESHEIMER (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 092. YPSOMED (SWITZERLAND): SNAPSHOT
TABLE 093. YPSOMED (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 094. YPSOMED (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 095. YPSOMED (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 095. B. BRAUN MELSUNGEN (GERMANY): SNAPSHOT
TABLE 096. B. BRAUN MELSUNGEN (GERMANY): BUSINESS PERFORMANCE
TABLE 097. B. BRAUN MELSUNGEN (GERMANY): PRODUCT PORTFOLIO
TABLE 098. B. BRAUN MELSUNGEN (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY TYPE
FIGURE 012. DEVICES MARKET OVERVIEW (2016-2027)
FIGURE 013. FORMULATIONS MARKET OVERVIEW (2016-2027)
FIGURE 014. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY PACKAGING FORMULATIONS
FIGURE 015. AMPOULES MARKET OVERVIEW (2016-2027)
FIGURE 016. VIALS MARKET OVERVIEW (2016-2027)
FIGURE 017. CARTRIDGES MARKET OVERVIEW (2016-2027)
FIGURE 018. BOTTLES MARKET OVERVIEW (2016-2027)
FIGURE 019. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY THERAPEUTIC APPLICATION
FIGURE 020. AUTOIMMUNE DISEASES MARKET OVERVIEW (2016-2027)
FIGURE 021. HORMONAL DISORDERS MARKET OVERVIEW (2016-2027)
FIGURE 022. ORPHAN DISEASES MARKET OVERVIEW (2016-2027)
FIGURE 023. CANCER MARKET OVERVIEW (2016-2027)
FIGURE 024. OTHERS MARKET OVERVIEW (2016-2027)
FIGURE 025. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY USAGE PATTER
FIGURE 026. CURATIVE CARE MARKET OVERVIEW (2016-2027)
FIGURE 027. IMMUNIZATION MARKET OVERVIEW (2016-2027)
FIGURE 028. OTHERS MARKET OVERVIEW (2016-2027)
FIGURE 029. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY SITE OF ADMINISTRATION
FIGURE 030. SKIN MARKET OVERVIEW (2016-2027)
FIGURE 031. CIRCULATORY/MUSCULOSKELETAL SYSTEM MARKET OVERVIEW (2016-2027)
FIGURE 032. ORGANS MARKET OVERVIEW (2016-2027)
FIGURE 033. CENTRAL NERVOUS SYSTEM MARKET OVERVIEW (2016-2027)
FIGURE 034. INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY DISTRIBUTION CHANNEL
FIGURE 035. HOSPITAL MARKET OVERVIEW (2016-2027)
FIGURE 036. RETAIL PHARMACY STORES MARKET OVERVIEW (2016-2027)
FIGURE 037. NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY COUNTRY (2016-2027)
FIGURE 038. EUROPE INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY COUNTRY (2016-2027)
FIGURE 039. ASIA PACIFIC INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY COUNTRY (2016-2027)
FIGURE 040. MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY COUNTRY (2016-2027)
FIGURE 041. SOUTH AMERICA INJECTABLE DRUG DELIVERY DEVICES MARKET OVERVIEW BY COUNTRY (2016-2027)

LICENSE TYPE

Inquiry Before Buying


SPECIAL PRICES

For startups and educational institutions.

Request Discount 

CUSTOMIZATION

IMR offers custom market research services as per customer requirements.

Request Customization 




Why Choose Us


Reliable Market Service

We provide accurate market insights and effective consulting to achieve your goals.


Holistic Market View

We provide in-depth knowledge of the market which enables our clients to take informed decisions at minimum risks.


Innovative Methodology

Our world class researchers use big data and advanced analytics to not only provide accurate insights, but spot future trends and help you you grow.


Customer Centric

We strive to deliver deep understanding of the elements which are pivotal to prosperity of our clients.


24/7 Support

Our dedicated support team is here to help you in every aspect.


Introspective Market Research
Loading....Please Wait